Does the timing of esophagectomy after chemoradiation affect outcome?
- PMID: 21962263
- PMCID: PMC4041623
- DOI: 10.1016/j.athoracsur.2011.05.021
Does the timing of esophagectomy after chemoradiation affect outcome?
Abstract
Background: After neoadjuvant chemoradiation (CXRT) for esophageal cancer, surgery has traditionally been recommended to be performed within 8 weeks. However, surgery is often delayed for various reasons. Data from other cancers suggest that delaying surgery may increase the pathologic complete response rate. However, there are theoretical concerns that waiting longer after radiation may lead to a more difficult operation and more complications. The optimal timing of esophagectomy after CXRT is unknown.
Methods: From a prospective database, we analyzed 266 patients with resected esophageal cancer who were treated with neoadjuvant CXRT from 2002 to 2008. Salvage resections were excluded from this analysis. We compared patients who had surgery within 8 weeks of CXRT and those who had surgery after 8 weeks. We used multivariable analysis to determine whether increased interval between chemoradiation and surgery was independently associated with perioperative complication, pathologic response, or overall survival.
Results: One hundred fifty patients were resected within 8 weeks and 116 were resected greater than 8 weeks after completing CXRT. Mean length of operation, intraoperative blood loss, anastomotic leak rate, and perioperative complication rate were similar for the two groups. Pathologic complete response rate and overall survival were also similar for the two groups (p=not significant). In multivariable analysis, timing of surgery was not an independent predictor of perioperative complication, pathologic complete response, or overall survival.
Conclusions: The timing of esophagectomy after neoadjuvant CXRT is not associated with perioperative complication, pathologic response, or overall survival. It may be reasonable to delay esophagectomy beyond 8 weeks for patients who have not yet recovered from chemoradiation.
Copyright © 2012 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.
Figures
Similar articles
-
Esophagectomy Timing After Neoadjuvant Therapy for Distal Esophageal Adenocarcinoma.Ann Thorac Surg. 2016 Mar;101(3):1123-30. doi: 10.1016/j.athoracsur.2015.09.044. Epub 2015 Dec 1. Ann Thorac Surg. 2016. PMID: 26652139
-
Factors affecting postoperative course and survival after en bloc resection for esophageal carcinoma.Ann Thorac Surg. 2004 Oct;78(4):1177-83. doi: 10.1016/j.athoracsur.2004.02.068. Ann Thorac Surg. 2004. PMID: 15464466 Review.
-
Multimodality treatment for esophageal cancer: the role of surgery and neoadjuvant therapy.Am Surg. 2003 Aug;69(8):693-700; discussion 700-2. Am Surg. 2003. PMID: 12953828
-
Does timing of esophagectomy following neoadjuvant chemoradiation affect outcomes? A meta-analysis.Int J Surg. 2018 Nov;59:11-18. doi: 10.1016/j.ijsu.2018.09.013. Epub 2018 Sep 24. Int J Surg. 2018. PMID: 30261331 Review.
-
Influence of Neoadjuvant Radiation Dose on Patients Undergoing Esophagectomy and Survival in Locally Advanced Esophageal Cancer.J Gastrointest Surg. 2019 Apr;23(4):670-678. doi: 10.1007/s11605-019-04141-z. Epub 2019 Feb 20. J Gastrointest Surg. 2019. PMID: 30788714
Cited by
-
[Timing of esophagectomy in multimodal therapy of esophageal cancer: Impact of time interval between neoadjuvant therapy and surgery on outcome and response].Chirurg. 2015 Sep;86(9):874-80. doi: 10.1007/s00104-014-2916-6. Chirurg. 2015. PMID: 25662991 German.
-
The enhanced recovery after surgery (ERAS) protocol to promote recovery following esophageal cancer resection.Surg Today. 2020 Apr;50(4):323-334. doi: 10.1007/s00595-020-01956-1. Epub 2020 Feb 11. Surg Today. 2020. PMID: 32048046 Free PMC article. Review.
-
18F-FDG PET-CT after Neoadjuvant Chemoradiotherapy in Esophageal Cancer Patients to Optimize Surgical Decision Making.PLoS One. 2015 Nov 3;10(11):e0133690. doi: 10.1371/journal.pone.0133690. eCollection 2015. PLoS One. 2015. PMID: 26529313 Free PMC article.
-
Impact of the interval between neoadjuvant immunotherapy and surgery on prognosis in esophageal squamous cell carcinoma (ESCC): a real-world study.Cancer Immunol Immunother. 2024 Aug 6;73(10):202. doi: 10.1007/s00262-024-03787-2. Cancer Immunol Immunother. 2024. PMID: 39105817 Free PMC article.
-
Association between time interval from neoadjuvant chemoradiotherapy to surgery and complete histological tumor response in esophageal and gastroesophageal junction cancer: a national cohort study.Dis Esophagus. 2020 May 15;33(5):doz078. doi: 10.1093/dote/doz078. Dis Esophagus. 2020. PMID: 31676895 Free PMC article. Clinical Trial.
References
-
- Gebski V, Burmeister B, Smithers BM, et al. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol. 2007;8(3):226–234. - PubMed
-
- Walsh TN, Noonan N, Hollywood D, et al. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med. 1996;335(7):462–467. - PubMed
-
- Bosset JF, Gignoux M, Triboulet JP, et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med. 1997;337(3):161–167. - PubMed
-
- Burmeister BH, Smithers BM, Gebski V, et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol. 2005;6(9):659–668. - PubMed